| Name | Title | Contact Details |
|---|
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Beacon Biotechnology is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.